Name: NEKTAR THERAPEUTICS (NKTR) Stock
Brand: NEKTAR THERAPEUTICS
Rating: 6.5 (3 reviews)

NKTR Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Chartmill

Nektar Therapeutics (NASDAQ:NKTR) Q3 2025 Earnings Top Estimates, Sending Shares Higher

5 days ago - By: The Motley Fool - Mentions: CDTX BMRN MRK

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.

12 days ago - By: Zacks Investment Research

Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?

17 days ago - By: Nektar Therapeutics

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

18 days ago - By: Zacks Investment Research - Mentions: LLY ANIP ACAD

Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

19 days ago - By: Zacks Investment Research - Mentions: MDWD

Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates

19 days ago - By: Nektar Therapeutics

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

19 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

22 days ago - By: Zacks Investment Research - Mentions: GRDN

Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

26 days ago - By: Nektar Therapeutics

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

a month ago - By: Zacks Investment Research - Mentions: OABI

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

a month ago - By: Nektar Therapeutics

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

a month ago - By: Nektar Therapeutics

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

3 months ago - By: Zacks Investment Research - Mentions: REGN SNY LLY

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

3 months ago - By: Nektar Therapeutics

Nektar Therapeutics to Participate in Two Investor Conferences in September

4 months ago - By: Zacks Investment Research - Mentions: LLY CRMD IMCR

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

4 months ago - By: The Motley Fool

Nektar (NKTR) Q2 Revenue Falls 52%

4 months ago - By: Zacks Investment Research - Mentions: MDWD

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Nektar Therapeutics

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

4 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

4 months ago - By: Zacks Investment Research - Mentions: RIGL

Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates

4 months ago - By: Zacks Investment Research - Mentions: LLY CRMD AMRX

Nektar Gears Up to Report Q2 Earnings: What's in the Cards?

4 months ago - By: Zacks Investment Research - Mentions: DERM

Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release